November 6, 2017 06:28 AM EST

For 3rd time, the FDA and its new commissioner dropped safety issues and trial demands, clearing the path for snubbed therapy

John Carroll

Editor & Founder

TherapeuticsMD $TXMD was slammed on May 8 when the FDA formally rejected its application for a vaginal pain medicine dubbed TX-004HR. Regulators wanted more …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

For 3rd time, the FDA and its new commissioner dropped safety issues and trial demands, clearing the path for snubbed therapy

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

FDA approves Ionis’ treatment for a rare metabolic disorder

For 3rd time, the FDA and its new com­mis­sion­er dropped safe­ty is­sues and tri­al de­mands, clear­ing the path for snubbed ther­a­py

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

For 3rd time, the FDA and its new commissioner dropped safety issues and trial demands, clearing the path for snubbed therapy

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

FDA approves Ionis’ treatment for a rare metabolic disorder